anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is a further observation and follow-up of the patients enrolled in the registration number NCT06341270 to further evaluate the efficacy of TEAS on postoperative chronic pain and survival in patients undergoing hepatectomy. Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS）or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6), Hegu (L14), Yanglingquan (GB34), Zusanli (ST 36) and Renying (ST9) acupoints. Patients will receive TEAS 30 min before anesthesia until being discharged from the post-anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient. Patients in the sham group will receive electrode attachment but without stimulation. Follow-up after discharge includes chronic pain, the impact of chronic pain on quality of life, the relapse-free survival, overall survival at 3 months and 6 months postoperatively.
The use of a composition for arresting, protecting and or preserving an organ. The organ may include a heart, and may be an organ originating from the circulation, respiratory, urinary, digestive, reproductive and neurological systems. The composition includes: a) either or both a potassium channel opener or agonist, and an adenosine receptor agonist, and b) a local anaesthetic. The potassium channel opener or agonist may include the following: Nicorandil, diaoxide, minoxidil, filodipine, verapamil, pimiozide, and nimodipine. The adenosine receptor agonist may include: N6-cyclopentyladenosine, N-ethylcarboxamido adenosine and 2- chloroadenosine. The local anaethetic may include the following: Mexiletine, class 1B antiarrhythmic agent such as lignocaine, prilocaine, and mipivacaine.
The present invention provides methods of improving phenotypic defects that are caused by conformationally defective target proteins. The methods of the invention comprise exposing a cell that expresses a conformationally defective target protein with an amount of a protein stabilizing agent that is effective to improve the phenotypic defect. Nonlimiting examples of protein stabilizing agents include dimethylsulfoxide (DMSO), deuterated water, trimethylamine N-oxide (TMAO). Nonlimiting examples of defective target proteins to be treated include the cystic fibrosis transmembrane conductance regulator (CFTR) protein and prion proteins. In one embodiment, the invention provides methods for detecting protein stabilizing agents. In another embodiment, the invention provides methods for detecting cells and pathological conditions caused by improper folding and protein processing.
PURPOSE: To obtain an oil and fat-containing tablet rapidly disintegrating in an oral cavity, having smoothness without roughness, excellent in touch in an oral cavity. CONSTITUTION: This tablet contains both a first granule comprising oils and fats and an excipient as essential components and a second granule comprising an excipient as an essential component but not fats and oils and is obtained by compression molding. The excipient is a water-soluble saccharide such as a monosaccharide, an oligosaccharide, a sugar alcohol, etc., and its amount is 70-93wt.% based on the whole first granule and 85-97wt.% based on the whole tablet. The oils and fats are solid at a normal temperature, have 30-37 deg.C melting point or are mixed with the excipient to show 30-37 deg.C melting point and are vegetable oils and fats (e.g. corn oil), animal oils and fats (e.g. cream) and hard fats. The amount of the oils and fats contained is 70-30wt.% based on the whole first granule and 3-20wt.% based on the whole tablet.  The whole tablet is mixed with 0.001-40wt.% of a pharmacodynamically effective component and properly a lubricant, a flavor, a colorant, etc., and pharmaceutically manufactured.
The invention discloses a traditional Chinese medicine for treating duodenal ulcer and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine is prepared from raw rhizoma pinelliae, eggshell, honey-fried liquorice root, semen litchi and fructus aurantii. The compatibility of the traditional Chinese medicine is as follows: 20-30g of the raw rhizoma pinelliae, 20-30g of the eggshell, 40-60g of the honey-fried liquorice root, 10-23g of the semen litchi and 1-14g of the fructus aurantii. The preparation method of the traditional Chinese medicine comprises the following steps: decocting 20-30g of the raw rhizoma pinelliae, 20-30g of the eggshell, 40-60g of the honey-fried liquorice root, 10-23g of the semen litchi and 1-14g of the fructus aurantii with 160-480g of water above slow fire for 10-30min, filtering and reserving a filtrate, so that a finished product is obtained. The traditional Chinese medicine disclosed by the invention has functions of promoting digestion, clearing away heat and toxic materials, eliminating stagnation and the like. The traditional Chinese medicine is mainly used for treating gastroptosis and edema; and the traditional Chinese medicine has the characteristics of being short in treatment course, high in cure rate, not easy for reoccurrence and the like.
Pain is frequently encountered in dermatology practice, which impairs the activities of daily living, adds to psychological morbidity, and therefore compromises the quality of life. It ranges from mild to severe in intensity across various dermatoses and requires prompt addressal and treatment. Diseases such as extensive pemphigus vulgaris and Stevens-Johnson syndrome are especially painful and require a multidisciplinary approach with the involvement of a pain specialist in their management. The main pathogenic types of pain include visceral nociceptive, somatic nociceptive, and neuropathic types, the latter two being most relevant in dermatological disorders. Somatic nociceptive pain is often seen in patients of Stevens-Johnson syndrome/ Toxic epidermal necrolysis, epidermolysis bullosa, pemphigus vulgaris, erythema nodosum, and hidradenitis suppurativa, while neuropathic pain is part of the disease process in dermatoses like leprosy, herpes zoster, and dysesthesia syndromes. Therapeutic approaches to pain management include the use of non-opioids (acetaminophen, non-steroidal anti-inflammatory agents), opioids, and non-pharmacological therapies, along with appropriate management of the underlying dermatosis. World Health Organisation (WHO) analgesic ladder remains the most commonly employed guideline for the management of pain, although treatment needs individualisation depending on the nature and severity of pain (acute/chronic), type of dermatosis, and patient factors. There is a paucity of literature pertaining to pain management in dermatology and this topic is often neglected due to a lack of awareness and knowledge of the topic. The present review aims to discuss the pain pathway, various painful conditions in the setting of medical dermatology practice, and their management along with relevant pharmacology of the commonly used analgesics.
The spinal cord stimulators WaveWriter AlphaTM (Boston Scientific) are designed to treat chronic back or leg pain by electrically stimulating the spinal cord. It is a well established worldwide licensed device. Percutaneous lead(-s) are implanted in the epidural space of the thoracic spine during the initial procedure. After discharge a trial phase is initiated and performed according to local preferences and standard of operations (SOPs). Patients are monitored for any complications and pain reduction. If a significant pain reduction (\>50 % on the NRS scale for back pain) is achieved, the permanent implantable pulse generator (IPG) is implanted. Otherwise if the therapy remains non-beneficial throughout the trial phase, the leads will be explanted. Patients are allowed to crossover in the fusion group at any point of time.
Oxcarbazepine oral suspension can be taken with or without food [see Clinical Pharmacology (12.3)].

Before using oxcarbazepine oral suspension, shake the bottle well and prepare the dose immediately afterwards. The prescribed amount of oral suspension should be withdrawn from the bottle using the oral dosing syringe supplied. Oxcarbazepine oral suspension can be mixed in a small glass of water just prior to administration, or alternatively, may be swallowed directly from the syringe. After each use, close the bottle and rinse the syringe with warm water, and allow it to dry thoroughly.

Oxcarbazepine oral suspension and oxcarbazepine film-coated tablets may be interchanged at equal doses.
1,248,472. Cycloheptimidazole derivatives. RAVIZZA S.A. 1 Aug., 1969 [8 Aug., 1968], No. 38022/68. Heading C2C. Novel compounds I in which R is phenyl optionally substituted by one or two of the radicals 1-3 C alkyl or 1-3 C alkoxy or by halo or is 3-pyridyl optionally containing a methyl substituent and their acid addition salts are prepared by reaction of RNCO with 2-amino-tropane. Pharmaceutical compositions comprise a compound I together with a suitable carrier, are administered orally or rectally and have antiinflammatory, anti - oedema, anti - exudative, antipyretic and analgesic activity.
The present invention relates to 1,2,4,5-tetrasubstituted imidazole derivatives as selective cannabinoid CB1 receptor modulators, in particular CB1 receptor antagonists or inverse agonists having a high CB1/CB2 receptor subtype selectivity, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said imidazole derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.
The present invention provides a substituted dihydroisoquinoline derivative or the pharmaceutically acceptable salt thereof having the effect for inhibiting cell response of intracellular signal transmission or cell activation induced by endotoxin and therefore over produced the inflammatory mediator etc. , and a medicine containing them as the active ingredient, and a process for preparing thereof. The present invention also provides a medicine containing, as the active ingredient, said substituted dihydroisoquinoline derivative, which is an excellent prophylactic and/ or therapeutic drug for the diseases of the intracellular signal transmission or cell activation induced by endotoxin and the cell response related septicemia (septicemia shock, disseminated intravascular coagulation syndrome, multiple organ failure etc.) etc. caused by them. The compound has the following formula (I): or the pharmaceutically acceptable salt thereof, and the medicine contains, as the active ingredient, said compound.
Each of the 6 participants while still inside the MRI exam room just after the MRI in fast condition, will ingest 200mL of the study oral supplement (OS). The individual will be immediately positioned in the supine position and another MRI scan will be carried out. In this second phase, GRV will be evaluated again as in phase 1 (phase 2).
Several medical teams have recently shown that disturbances of smell and taste are common and can be a precursor and even an isolated sign of COVID-19 involvement. Preliminary results suggest the presence of clinical MRI abnormalities, particularly in the olfactory bulbs in anosmic patients with COVID-19.

Anosmia and taste disturbance are early warning signs that could be important in improving the detection and diagnosis of COVID-19, and also in monitoring disease. In addition, disturbances in smell and taste could be an aid in establishing the prognosis of the clinical course of the viral disease. The question of olfactory recovery is also fundamental. To date, we do not know the possibilities of recovery from COVID-19 post viral anosmia. ENT exams, olfactometry and MRI are proposed to study these phenomena.
Participants will received an 8-week intervention consisting of exercise. The exercise performed in this group will be the same as in the intervention group and will follow the same international guidelines for chronic NP.
PURPOSE:To obtain globulin and albumin useful a raw material for foods, feeds, drugs, etc. simply and economically, by adding a Ca solution to animal plasma so that it is adjusted to a specific pH, fractionating precipitated fibrinogen effectively. CONSTITUTION:A plasma fraction is collected from blood of animal such as swine, bovine, etc. by a common separation method, an aqueous solution of a Ca salt or calcium hydroxide is added to the plasma, and the solution is adjusted to 6-10 pH, preferably 7-9 pH, so that precipitated fibrinogen is agglomerated and fractionated effectively, to collect plasma protein of globulin and albumin. An amount of the Ca solution added is properly 0.02-0.08 molar concentration based on plasma. This method is different from conventional ammonium sulfate method, sodium sulfate method, ethanol fractionation method, heavy metal salt method, etc., and it is simple and economically advantageous.
BACKGROUND: The relationship between human gut microbiota and high-altitude hypoxia acclimatization remains highly controversial. This stems primarily from uncertainties regarding both the potential temporal changes in the microbiota under such conditions and the existence of any dominant or core bacteria that may assist in host acclimatization.
RESULTS: To address these issues, and to control for variables commonly present in previous studies which significantly impact the results obtained, namely genetic background, ethnicity, lifestyle, and diet, we conducted a 108-day longitudinal study on the same cohort comprising 45 healthy Han adults who traveled from lowland Chongqing, 243 masl, to high-altitude plateau Lhasa, Xizang, 3658 masl, and back. Using shotgun metagenomic profiling, we study temporal changes in gut microbiota composition at different timepoints. The results show a significant reduction in the species and functional diversity of the gut microbiota, along with a marked increase in functional redundancy. These changes are primarily driven by the overgrowth of Blautia A, a genus that is also abundant in six independent Han cohorts with long-term duration in lower hypoxia environment in Shigatse, Xizang, at 4700 masl. Further animal experiments indicate that Blautia A-fed mice exhibit enhanced intestinal health and a better acclimatization phenotype to sustained hypoxic stress.
CONCLUSIONS: Our study underscores the importance of Blautia A species in the gut microbiota's rapid response to high-altitude hypoxia and its potential role in maintaining intestinal health and aiding host adaptation to extreme environments, likely via anti-inflammation and intestinal barrier protection.
INTRODUCTION: Lifestyle factors, including inadequate eating patterns, emerge as a critical determinant of chronic disease. Apart from caring for patients, nurses should also take an active role in monitoring and managing their own health. Understanding the intricate relationship between nurses' eating behavior and managing their own health is crucial for fostering a holistic approach to healthcare, therefore our study aimed to evaluate eating behavior and demographic factors influencing chronic disease prevalence in a sample of community nurses from Romania.
METHODS: Between October-November 2023, 1920 community nurses were invited to answer an online survey, using an advertisement in their professional network. Of them, 788 responded. In the survey, which included a semi-quantitative food frequency questionnaire with 53 food items, the Intuitive Eating Survey 2 (IES-2), and demographic items were used.
RESULTS: A multivariate model was built for the prediction of the association between eating behavior and other factors associated with chronic diseases. The majority of participants were females (95.1%), with the largest age group falling between 40 and 49.9 years (48.2%). Regarding the EFSA criteria for adequate carbohydrate and fat intake, 20.2% of the group have a high intake of carbohydrates, respectively, 43.4% of the group have a high intake of fat. Analysis of chronic diseases indicated that 24.9% of individuals reported at least one diagnosis by a physician. The presence of chronic disease was associated with a low level of perceived health status, with an OR = 3.388, 95%CI (1.684-6.814), compared to those reporting excellent or very good perceived health status. High stress had an OR = 1.483, 95%CI (1.033-2.129). BMI had an OR = 1.069, 95%CI (1.032-1.108), while low carbohydrate diet score had an OR = 0.956, 95%CI (0.920-0.992). Gender and IES-2 did not significantly contribute to the model, but their effect was controlled.
DISCUSSION: By unraveling the intricate interplay between nutrition, lifestyle, and health outcomes in this healthcare cohort, our findings contribute valuable insights for the development of targeted interventions and support programs tailored to enhance the well-being of community nurses and, by extension, the patients they support.
INTRODUCTION: Atrioventricular nodal reentrant tachycardia (AVNRT) is the most common supraventricular tachycardia referred for ablation. Periprocedural conduction system damage was a primary concern during AVNRT ablation. This study aimed to assess the incidence of permanent atrioventricular (AV) block and the success rate associated with different types of catheters in slow pathway ablation.
METHOD: A literature search was performed to identify studies that compared various techniques, including types of radiofrequency ablation (irrigated and nonirrigated) and different sizes of catheter tip cryoablation (4, 6, and 8-mm), in terms of their outcomes related to permanent atrioventricular block and success rate. To assess and rank the treatments for the different outcomes, a random-effects model of network meta-analysis, along with p-scores, was employed.
RESULTS: A total of 27 studies with 5110 patients were included in the analysis. Overall success rates ranged from 89.78% to 100%. Point estimation showed 4-mm cryoablation exhibited an odds ratio of 0.649 (95%CI: 0.202-2.087) when compared to nonirrigated RFA. Similarly, 6-mm cryoablation had an odds ratio of 0.944 (95%CI: 0.307-2.905), 8-mm cryoablation had an odds ratio of 0.848 (95%CI: 0.089-8.107), and irrigated RFA had an odds ratio of 0.424 (95%CI: 0.058-3.121) compared to nonirrigated RFA.
CONCLUSION: Our study found no significant difference in the incidence of permanent AV block between the types of catheters. The success rates were consistently high across all groups. These findings emphasize the potential of both RF ablation (irrigated and nonirrigated catheter) and cryoablation as viable options for the treatment of AVNRT, with similar safety and efficacy profile.
FIELD: hygiene.SUBSTANCE: group of inventions relates to the field of oral care and pertains to an application of polymer particles for introducing agents for oral care into the oral cavity of the subject, as well as to a system and method for such introduction, a set of parts, and a composition for application in such introduction. Proposed is an application of one or more polymer particles for delivering an agent for oral care, wherein each of the particles has at least one geometric size equal to or less than 1.5 millimeters and has the smallest geometric size of at least 0.1 mm (wherein the geometric dimensions constitute the length, width, height, diagonal of the body, or diameter of said particle), and comprises a superabsorbent polymer (SAP) selected from the group consisting of crosslinked polymers based on sodium polyacrylate; a copolymer of polyacrylamide, a copolymer of ethylene maleic anhydride, cross-linked carboxymethyl cellulose, copolymers of polyvinyl alcohol, cross-linked polyethylene oxide, and a copolymer of grafted starch with polyacrylonitrile. The system comprises a first container for storing the above particles, a second container for storing the agent for oral care, and an applicator for interdental delivery of polymer particles containing the above agent. The set of parts includes a first part containing the above particles and a second part containing the agent for oral care. The composition for delivering the agent for oral care comprises one or more of the above polymer particles and the agent for oral care. The method for introducing the agent for oral care includes delivery of the above polymer particles to the oral cavity, wherein each particle comprises the agent for oral care. The size of the particles ensures easy delivery thereof to the interdental space.EFFECT: significant increase in the volume of particles on contact thereof with saliva, due to the capability of SAP for absorbing water several times greater than own mass, prevents quick washing thereof from the interdental space, providing prolonged release of the agent for oral care.23 cl, 2 ex, 3 dwg
The Phase I study proposed is a randomized, double-blind, placebo-controlled evaluation of the safety and pharmacokinetics of escalating single oral doses of oxfendazole (0.3 to 30 mg/kg) in healthy volunteers. The dose will be increased approximately three-fold (one-half log) at each increment, and each cohort will comprise ten volunteers (eight drug, two placebo). Subjects will be monitored for three weeks after dosing, including monitoring the pharmacokinetics and metabolism of oxfendazole in blood and urine. Each new cohort will be dosed only after the three week safety data for the preceding group have been analyzed. If a clinically significant adverse event is observed, and if this event is possibly drug-related, an additional (and final) cohort of volunteers will repeat the highest tolerated dose of oxfendazole. Up to 70 volunteers (56 drug, 14 placebo) will complete the study.